Abstract
Sirolimus is an effective oral treatment for pediatric patients with lymphangioma. The present clinical study in 15 children (0.12–16.39 years of age) examines the effects of underlying factors on sirolimus concentrations through application of a population pharmacokinetic model. Using Monte Carlo simulation, an initial dose regimen for sirolimus in pediatric patients with lymphangioma is presented. It is found that the lower the body weight, the higher the clearance rate and sirolimus clearances are 0.31–0.17 L/h/kg in pediatric patients with lymphangioma whose weights are 5–60 kg, respectively. The doses of sirolimus, 0.07, 0.06, 0.05 mg/kg/day are recommended for weights of 5–10, 10–24.5 and 24.5–60 kg in children with lymphangioma. This study is the first to establish a population pharmacokinetic model for sirolimus and to recommend initial doses in pediatric patients with lymphangioma. Large scale, prospective studies are needed in the future.
Highlights
Lymphangioma, which is called lymphatic malformation, is rare and benign anomaly derived from the defective embryological development of the primordial lymphatic structure (Amodeo et al, 2017b)
The present study aims to investigate the effects of underlying factors on clinical sirolimus concentrations by building up a population pharmacokinetic model, and to recommend initial dose regimen for sirolimus in pediatric patients with lymphangioma using Monte Carlo simulation
A total of 15 pediatric patients with lymphangioma are included in the present study, 12 boys and 3 girls, aged from 0.12 to 16.39 years old and weighted from 4 to 54 kg
Summary
Lymphangioma, which is called lymphatic malformation, is rare and benign anomaly derived from the defective embryological development of the primordial lymphatic structure (Amodeo et al, 2017b). Disease progress includes the progressive growth of the lymphangioma leading to compression of the adjacent structures (Reinglas et al, 2011). On account of their permeative growth throughout all tissue layers, treatment is often challenging and controversial (Laforgia et al, 2016; Amodeo et al, 2017b). The present study aims to investigate the effects of underlying factors on clinical sirolimus concentrations by building up a population pharmacokinetic model, and to recommend initial dose regimen for sirolimus in pediatric patients with lymphangioma using Monte Carlo simulation
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
